CoChat

Anti-angiogenic treatment strategies for the therapy of endometriosis

Open access
Laschke, M.W., Menger, M.D. · 2012 · Human Reproduction Update
Cited by 153

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

ResultsGrowth factor inhibitors Endogenous angiogenesis inhibitors Fumagillin analogues Statins Cyclo-oxygenase (COX)-2 inhibitors Phytochemical compounds Immunomodulators Dopamine agonists Peroxisome proliferator-activated receptor (PPAR) agonists Progestins, danazol and gonadotropin-releasing hormone (GnRH) agonists Other agents † Potential impact of anti-angiogenic treatment in future endometriosis therapy † Conclusionsbackground: Angiogenesis, i.e. the development of new blood vessels from pre-existing ones, represents an integral part in the pathogenesis of endometriosis.During the last decade, an increasing number of studies have therefore focused on the anti-angiogenic treatment of the disease.The present review provides a systematic overview of these studies and critically discusses the future role of anti-angiogenic therapy in the multimodal management of endometriosis.methods: Literature searches were performed in PubMed, MEDLINE and ISI Web of Knowledge for original articles published before the end of March 2012, written in the English language and focusing on anti-angiogenic approaches for the therapy of endometriosis.The searches included both animal and human studies.results: Numerous compounds of different substance groups have been shown to exert anti-angiogenic effects on endometriotic lesions under experimental in vitro and in vivo conditions.These include growth factor inhibitors, endogenous angiogenesis inhibitors, fumagillin analogues, statins, cyclo-oxygenase-2 inhibitors, phytochemical compounds, immunomodulators, dopamine agonists, peroxisome proliferator-activated receptor agonists, progestins, danazol and gonadotropin-releasing hormone (GnRH) agonists.However, clinical evidence for their efficacy in anti-angiogenic endometriosis therapy is still lacking.conclusions: Anti-angiogenic compounds hold great promise for the future treatment of endometriosis because they may inhibit the establishment of new endometriotic lesions in early stages of the disease or after surgical treatment.Further experimental studies, controlled clinical trials in particular, are required now to clarify which compounds fulfil these expectations without inducing severe side effects in patients with endometriosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/humupd/dms026

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 153

Metadata

Authors
Laschke, M. W., & Menger, M. D.
Venue
Human Reproduction Update
Published
2012-06-19
Volume
18
Issue
6
Pages
682-702
ISSN
  • 1355-4786 (ISSN-L)
  • 1460-2369
OpenAlex
W2111141200
Cited by
153
References
26
FWCI
14.39
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.